Vericel (VCEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.19-0.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VCEL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks VCEL against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue driving strong revenue and profit growth across MACI and Burn Care franchises with sustained cash flow generation and raised full-year revenue guidance.
Stated as a priority in 4 of last 4 quarters. Total net revenue grew from $52.6M in 2026-Q1 to $77.5M in 2026-Q2 (+22% YoY), with first half 2026 revenue up 26% to $145.9M. Full-year 2026 revenue guidance was raised to $330-$340M. Management consistently emphasizes sustained high revenue, profit, and cash flow growth, and the financials show delivering trajectory.
“Company is well-positioned for sustained high revenue, profit, and cash flow growth in 2026 and beyond.”
“Well-positioned for another year of high revenue and profit growth, an inflection in cash generation.”
“Expect another year of high revenue and profit growth, an inflection in cash generation.”
“MACI revenue growth of 20% or more for the fifth consecutive quarter.”
Drive continued MACI revenue growth with expanded sales force, increased biopsies and implants, and regulatory progress including UK marketing authorization submission.
Stated as a priority in 4 of last 4 quarters. MACI revenue grew consistently: $53.5M in 2025-Q2 to $65.5M in 2026-Q2 (+23% YoY), with similar growth in prior quarters. Management highlights expanded sales force and UK marketing authorization submission. The trajectory is delivering sustained MACI revenue growth.
Increase Burn Care revenue through product adoption and market expansion, with guidance raised and strong quarterly growth.
Stated as a priority in 4 of last 4 quarters. Burn Care revenue grew 49% to $24.0M in first half 2026, with $12.0M in 2026-Q2 alone. Guidance was raised to $46-$50M for 2026. Management consistently emphasizes Burn Care growth, and the financials show delivering trajectory.
“Burn Care net revenue growth of 49% to $24.0 million in first half 2026; guidance raised to $46 to $50 million.”
Sustain profitability with targeted gross margin near 75% and adjusted EBITDA margin near 27% for full-year 2026.
Stated as a priority in 4 of last 4 quarters. Management reaffirmed full-year 2026 gross margin guidance near 75% and adjusted EBITDA margin near 27%. Actual gross margin was 72% in 2026-Q1 and 73% in 2026-Q2, showing stable profitability. The trajectory is delivering consistent margin performance aligned with guidance.
“Reaffirmed full-year profitability guidance of gross margin of approximately 75% and adjusted EBITDA margin of approximately 27%.”
Initiate and execute a $200 million share repurchase program reflecting confidence in sustained growth trajectory.
Newly stated in 2026-Q2. The Board authorized a $200 million share repurchase program reflecting management's confidence in the company's growth. No prior quarters mention this program. Financials show strong cash and investments position supporting this capital allocation.
“Board of Directors authorized $200 million share repurchase program.”
Over the trailing year it converted -4.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“MACI revenue growth of 20% or more for the fifth consecutive quarter; marketing authorization application submitted to U.K. MHRA.”
“MACI revenue growth of 22%; remain on track to submit MACI marketing authorization application to U.K. MHRA in 2026.”
“MACI revenue growth of 23%; completed MACI sales force expansion; on track to submit MACI marketing authorization application to U.K. MHRA in 2026.”
“MACI revenue growth of 20% or more for the fourth consecutive quarter.”
“Burn Care net revenue growth of 91% to $12.0 million in 2026-Q1.”
“Burn Care net revenue of $8.8 million in 2025-Q4.”
“Burn Care revenue guidance updated to approximately $10 million per quarter in second half 2025.”
“Reaffirmed full-year profitability guidance of gross margin of approximately 75% and adjusted EBITDA margin of approximately 27%.”
“Full-year 2025 gross margin expected to be 74% and adjusted EBITDA margin expected to be 26%.”
“Reaffirmed full-year profitability guidance of 74% gross margin and 26% adjusted EBITDA margin.”